Cell-penetrating peptides: Possibilities and challenges for drug delivery in vitro and in vivo

Molecules

Volumn 20, Issue 7, 2015, Pages 13313-13323

  Skotland, Tore ^a,b   Iversen, Tore Geir ^a,b   Torgersen, Maria Lyngaas ^a,b   Sandvig, Kirsten ^a,b,c  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Cell penetrating peptides; Cellular uptake; Drug delivery; Endocytosis; In vivo dose; Pharmaceutical development

Indexed keywords

CELL PENETRATING PEPTIDE;

ACTIVE TRANSPORT; ANIMAL; CELL MEMBRANE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENDOCYTOSIS; HUMAN; METABOLISM; PROCEDURES;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CELL MEMBRANE; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HUMANS;

EID: 84938651998     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules200713313     Document Type: Review

References (39)

1. Madani, F.; Lindberg, S.; Langel, U.; Futaki, S.; Graslund, A. Mechanisms of cellular uptake of cell-penetrating peptides. J. Biophys. 2011, 2011, 414729, doi:10.1155/2011/414729.
2. Milletti, F. Cell-penetrating peptides: Classes, origin, and current landscape. Drug Discov. Today 2012, 17, 850-860.
3. Lee, S.H.; Castagner, B.; Leroux, J.C. Is there a future for cell-penetrating peptides in oligonucleotide delivery? Eur. J. Pharm. Biopharm. 2013, 85, 5-11.
4. Copolovici, D.M.; Langel, K.; Eriste, E.; Langel, U. Cell-penetrating peptides: Design, synthesis, and applications. ACS Nano 2014, 8, 1972-1994.
5. Choi, Y.S.; David, A.E. Cell penetrating peptides and the mechanisms for intracellular entry. Curr. Pharm. Biotechnol. 2014, 15, 192-199.
6. Richard, J.P.; Melikov, K.; Vives, E.; Ramos, C.; Verbeure, B.; Gait, M.J.; Chernomordik, L.V.; Lebleu, B. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 2003, 278, 585-590.
7. Richard, J.P.; Melikov, K.; Brooks, H.; Prevot, P.; Lebleu, B.; Chernomordik, L.V. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J. Biol. Chem. 2005, 280, 15300-15306.
8. Duchardt, F.; Fotin-Mleczek, M.; Schwarz, H.; Fischer, R.; Brock, R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 2007, 8, 848-866.
9. Lundin, P.; Johansson, H.; Guterstam, P.; Holm, T.; Hansen, M.; Langel, U.; EL Andaloussi, S. Distinct uptake routes of cell-penetrating peptide conjugates. Bioconjugate Chem. 2008, 19, 2535-2542.
10. Magzoub, M.; Pramanik, A.; Graslund, A. Modeling the endosomal escape of cell-penetrating peptides: Transmembrane pH gradient driven translocation across phospholipid bilayers. Biochemistry 2005, 44, 14890-14897.
11. Tunnemann, G.; Martin, R.M.; Haupt, S.; Patsch, C.; Edenhofer, F.; Cardoso, M.C. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J. 2006, 20, 1775-1784.
12. Ter-Avetisyan, G.; Tunnemann, G.; Nowak, D.; Nitschke, M.; Herrmann, A.; Drab, M.; Cardoso, M.C. Cell entry of arginine-rich peptides is independent of endocytosis. J. Biol. Chem. 2009, 284, 3370-3378.
13. Ziegler, A.; Nervi, P.; Durrenberger, M.; Seelig, J. The cationic cell-penetrating peptide CPP(TAT) derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: Optical, biophysical, and metabolic evidence. Biochemistry 2005, 44, 138-148.
14. Sandvig, K.; Torgersen, M.L.; Raa, H.A.; van Deurs, B. Clathrin-independent endocytosis: From nonexisting to an extreme degree of complexity. Histochem. Cell Biol. 2008, 129, 267-276.
15. Wieffer, M.; Maritzen, T.; Haucke, V. SnapShot: Endocytic trafficking. Cell 2009, 137, 382-383.
16. Iversen, T.G.; Skotland, T.; Sandvig, K. Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies. Nano Today 2011, 6, 176-185.
17. Steinman, R.M.; Mellman, I.S.; Muller, W.A.; Cohn, Z.A. Endocytosis and the recycling of plasma membrane. J. Cell Biol. 1983, 96, 1-27.
18. Sandvig, K.; Pust, S.; Skotland, T.; van Deurs, B. Clathrin-independent endocytosis: Mechanisms and function. Curr. Opin. Cell Biol. 2011, 23, 413-420.
19. Schmid, S.L.; Sorkin, A.; Zerial, M. Endocytosis: Past, present, and future. Cold Spring Harb. Perspect. Biol. 2014, 6, a022509.
20. Kirchhausen, T.; Owen, D.; Harrison, S.C. Molecular structure, function, and dynamics of clathrin-mediated membrane traffic. Cold Spring Harb. Perspect. Biol. 2014, 6, a016725.
21. Mayor, S.; Parton, R.G.; Donaldson, J.G. Clathrin-independent pathways of endocytosis. Cold Spring Harb. Perspect. Biol. 2014, 6, a016758.
22. Parton, R.G.; del Pozo, M.A. Caveolae as plasma membrane sensors, protectors and organizers. Nat. Rev. Mol. Cell Biol. 2013, 14, 98-112.
23. Hayer, A.; Stoeber, M.; Ritz, D.; Engel, S.; Meyer, H.H.; Helenius, A. Caveolin-1 is ubiquitinated and targeted to intralumenal vesicles in endolysosomes for degradation. J. Cell Biol. 2010, 191, 615-629.
24. Varkouhi, A.K.; Scholte, M.; Storm, G.; Haisma, H.J. Endosomal escape pathways for delivery of biologicals. J. Control Release 2011, 151, 220-228.
25. Nischan, N.; Herce, H.D.; Natale, F.; Bohlke, N.; Budisa, N.; Cardoso, M.C.; Hackenberger, C.P. Covalent attachment of cyclic TAT peptides to GFP results in protein delivery into live cells with immediate bioavailability. Angew. Chem. Int. Ed 2015, 54, 1950-1953.
26. Berry, C.C. Intracellular delivery of nanoparticles via the HIV-1 tat peptide. Nanomedicine (Lond.) 2008, 3, 357-365.
27. Medintz, I.L.; Pons, T.; Delehanty, J.B.; Susumu, K.; Brunel, F.M.; Dawson, P.E.; Mattoussi, H. Intracellular delivery of quantum dot-protein cargos mediated by cell penetrating peptides. Bioconjugate Chem. 2008, 19, 1785-1795.
28. Ruan, G.; Agrawal, A.; Marcus, A.I.; Nie, S. Imaging and tracking of tat peptide-conjugated quantum dots in living cells: New insights into nanoparticle uptake, intracellular transport, and vesicle shedding. J. Am. Chem. Soc. 2007, 129, 14759-14766.
29. Nativo, P.; Prior, I.A.; Brust, M. Uptake and intracellular fate of surface-modified gold nanoparticles. ACS Nano 2008, 2, 1639-1644.
30. Skotland, T. Molecular imaging: Challenges of bringing imaging of intracellular targets into common clinical use. Contrast Media Mol. Imaging 2012, 7, 1-6.
31. Gilleron, J.; Querbes, W.; Zeigerer, A.; Borodovsky, A.; Marsico, G.; Schubert, U.; Manygoats, K.; Seifert, S.; Andree, C.; Stoter, M.; et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 2013, 31, 638-646.
32. Yamaizumi, M.; Mekada, E.; Uchida, T.; Okada, Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 1978, 15, 245-250.
33. Eiklid, K.; Olsnes, S.; Pihl, A. Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp. Cell Res. 1980, 126, 321-326.
34. Skotland, T.; Iversen, T.G.; Sandvig, K. Development of nanoparticles for clinical use. Nanomedicine 2014, 9, 1295-1299.
35. Pysz, M.A.; Gambhir, S.S.; Willmann, J.K. Molecular imaging: Current status and emerging strategies. Clin. Radiol. 2010, 65, 500-516.
36. Condeelis, J.; Weissleder, R. In vivo imaging in cancer. Cold Spring Harb. Perspect. Biol. 2010, 2, a003848, doi:10.1101/cshperspect.a003848.
37. Toft, K.G.; Johnson, J.A.; Oulie, I.; Skotland, T. NC100668, a new tracer tested for imaging of venous thromboembolism: Pharmacokinetics and metabolism in humans. Drug Metab. Dispos. 2007, 35, 1979-1984.
38. Roed, L.; Oulie, I.; McParland, B.J.; Skotland, T. Human urinary excretion of NC100692, an RGD-peptide for imaging angiogenesis. Eur. J. Pharm. Sci. 2009, 37, 279-283.
39. Nunn, A.D. The cost of developing imaging agents for routine clinical use. Investg. Radiol. 2006, 41, 206-212.